Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > 3 cents
View:
Post by Tomm613 on Dec 18, 2019 8:28am

3 cents

Nice start to the day with a .03 bid and ask.price.  LOL
Comment by simmer1965 on Dec 18, 2019 9:39am
so Canada.  The OSC should do their job.  Purely an attempt to manipulate
Comment by Canadian_101 on Dec 18, 2019 12:51pm
......its called the stock market,  prices go up prices go down, maybe people are taking profits on short term trades.... so Canada.  The OSC should do their job.  Purely an attempt to manipulate
Comment by nandolino123 on Dec 18, 2019 1:23pm
He was referring to the rediculous 3 cent bid/ask this morning
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities